login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ALLOGENE THERAPEUTICS INC (ALLO) Stock News
USA
- NASDAQ:ALLO -
US0197701065
-
Common Stock
1.29
USD
+0.06 (+4.88%)
Last: 10/20/2025, 8:00:00 PM
1.32
USD
+0.03 (+2.33%)
After Hours:
10/20/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ALLO Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Zacks Investment Research
- Mentions:
ADCT
ZTS
CMMB
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
7 days ago - By: Zacks Investment Research
- Mentions:
SNY
TEVA
CMMB
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
10 days ago - By: Zacks Investment Research
- Mentions:
CDTX
AKRO
CMMB
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
10 days ago - By: Benzinga
- Mentions:
HSBC
KEYS
AKRO
DOCS
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
a month ago - By: Zacks Investment Research
- Mentions:
BMY
PFE
LLY
ABBV
...
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
2 months ago - By: The Motley Fool
Allogene Narrows Loss in Fiscal Q2
2 months ago - By: Benzinga
A Look at Allogene Therapeutics's Upcoming Earnings Report
2 months ago - By: Zacks Investment Research
- Mentions:
ADPT
AQST
AKRO
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
2 months ago - By: Zacks Investment Research
- Mentions:
AGIO
ADPT
AKRO
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
2 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
2 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
2 months ago - By: Zacks Investment Research
- Mentions:
AMRN
AKRO
ALGS
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
2 months ago - By: The Motley Fool
Allogene Q2 Cash Tops $300 Million
2 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
2 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
3 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
3 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
3 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
3 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
3 months ago - By: Yahoo Finance
- Mentions:
REGN
BMY
BIIB
Regeneron cancer bispecific rejected again; Allogene discloses trial death
5 months ago - By: Zacks Investment Research
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy
5 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
5 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
5 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
5 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
5 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
5 months ago - By: Allogene Therapeutics, Inc.
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
Please enable JavaScript to continue using this application.